cdk 5

Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine kinase that is predominantly active in neuronal tissues. With p25 or p35, Cdk5 phosphorylates a range of proteins, including histone H1 and tau. Cdk5 Substrate acetate is a synthetic peptide (PKTPKKAKKL) corresponding to a sequence of histone H1. It is phosphorylated by Cdk5 with a Km value of 5 µM.

CDK5-IN-3 is a selective and potent CDK5 inhibitor that inhibits CDK5/p25 and CDK2/CycA and can be used in the study of cancer.

GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].

Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine kinase that is predominantly active in neuronal tissues. With p25 or p35, Cdk5 phosphorylates a range of proteins, including histone H1 and tau. Cdk5 substrate is a synthetic peptide (PKTPKKAKKL) corresponding to a sequence of histone H1. It is phosphorylated by Cdk5 with a Km value of 5 μM.

CDK5-IN-1 is a highly potent inhibitor of CDK5, displaying an inhibitory activity of less than 10 nM. This potent compound is specifically employed in scientific investigations relating to kidney diseases.

CDK5 inhibitor 20-223 （CP668863） is a potent CDK2/CDK5 inhibitor with IC50 values of 6.0 nm and 8.8 nM, respectively, with anti-Colorectal Cancer (CRC) potential, inhibiting cell migration and inducing cell cycle arrest in multiple CRC cell lines.

CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor targeting CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).

[pThr3]-CDK5 Substrate TFA, a potent Phospho-Thr3CDK5 Substrate, originates from the histone H1 peptide sequence that binds to CDK5's active site. This substrate undergoes phosphorylation by CDK5, demonstrating a K_m value of 6 µM [1].

CDK5-IN-4 (compound 4), a potent type-II multikinase inhibitor, targets CDK5 with an IC 50 of 9.8 μM. Additionally, it inhibits GSK-3α, GSK-3β, CDK9, and CDK2, demonstrating IC 50 values of 0.98, 4.00, 1.76, and 6.24 μM, respectively. This compound is applicable in glioblastoma research.

[pThr3]-CDK5 Substrate is an effective phospho-Thr3 CDK5 substrate that is phosphorylated by CDK5 with a Km value of 6 µM [1].

[pThr3]-CDK5 Substrate TFA is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM.

Dinaciclib (SCH 727965) is a selective CDK inhibitor targeting CDK1, CDK2, CDK5, and CDK9 (IC50 = 3/1/1/4 nM). It exhibits potential antitumor activity by inhibiting the incorporation of thoracic glycan (dThd) DNA.

GSK-3 inhibitor 4 is an orally active and brain-permeable compound that acts as a triple inhibitor of GSK-3, CDK2, and CDK5, with IC50 values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM (CDK2), and 0.68 μM (CDK5). It effectively reduces Tau protein levels and can be used in the study of Alzheimer's disease.

NVP-LCQ195 (LCQ-195) (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM).

Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of GSK-3β, CDK5, and CDK1, with IC50s of 80 nM, 5 nM, and 7 nM, respectively.

(R)-CR8 trihydrochloride (CR8, (R)-Isomer trihydrochloride) is a CDK1/2/5/7/9 inhibitor that acts as a molecular glue degrader with neuroprotective activity and induces apoptosis.

7-bromoindirubin-3'-oxime (7BIO) is a caspase independent nonapoptotic cell death inducer. 7BIO is an inhibitor of FLT3, DYRK1A, DYRK2, Aurora B and Aurora C kinases.

IC261 (SU-5607) is a novel inhibitor of CK1, triggers the mitotic checkpoint control. The IC50 of IC261 for CK1 was 16 μM and for Cdk5 is 4.5 mM.

BML-259 is an inhibitor of CDK5 and CDK2 with IC50s of 64 and 98 nM, respectively. BML-259 can be used in studies about the treatment of cancer and neurodegenerative diseases.

Purvalanol B (NG 95) is a CDK inhibitor that targets Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B, with IC50 values of 6, 9, 6, and 6 nM, respectively.

Alsterpaullone is a Cyclin-Dependent Kinase Inhibitor, Mediated Toxicity in HeLa Cells Through Apoptosis-Inducing Effec

5-Iodo-indirubin-3'-monoxime is a potent inhibitor of GSK-3β, CDK5/P25, and CDK1/cyclin B, competing with ATP for binding to the catalytic site of the kinase (IC50s: 9, 20, and 25 nM).

Olomoucine is an ATP-competitive inhibitor of Cdk2/cyclin A, Cdc2/CyclinB, CDK2/CyclinE, CDK5/p35, and ERK1/p44 MAP kinase with IC50s of 7, 7, 7, 3, and 25 µM, respectively. It regulates the cell cycle and exhibits anti-melanin tumor activities.

DSS30 is a P25/CDK5 inhibitor.DSS30 acts by inhibiting the phosphorylation of amyloid precursor protein cleaving enzyme 1 (BACEl), which reduces the secretion of β-amyloid (Aβ).DSS30 can be used for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease.